Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek July 18, 2005 John Carey	Is Heart Surgery Worth It? Physicians are questioning whether bypasses and angioplasties necessarily prolong patients' lives.
BusinessWeek June 9, 2009 John Carey	Giving Patients the Data They Need A growing effort by doctors, insurers, and politicians helps people make better-informed medical decisions
BusinessWeek October 29, 2007 Arlene Weintraub	Heart Trouble The tiny stent sparked a lucrative industry - and made Dr. Samin Sharma a star. Then questions arose about the device's safety and efficacy.
Managed Care December 2004 Martin Sipkoff	A Better Case for Quality: Share the Savings! Brent James's research has led to a new and powerful vision of paying for performance that binds physicians, plans and hospitals together.
BusinessWeek November 12, 2009 Catherine Arnst	10 Ways to Cut Health-Care Costs Right Now Employers and hospitals don't have to wait for Congress to address inefficiencies and waste.
BusinessWeek January 7, 2010 Catherine Arnst	Hospitals: Radical Cost Surgery A hospital that slashes costs - and delivers high-quality care as it innovates? Yes, it exists.
Pharmaceutical Executive November 1, 2013	Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation.
BusinessWeek October 9, 2006 John Carey	"No One Wanted To Hear" Renu Virmani warned that, over time, some drug-coated stents could lead to fatal clots.
Reason October 2007 Ronald Bailey	Is Industry-Funded Science Killing You? The overrated risks and underrated benefits of pharmaceutical research "conflicts of interest."
Pharmaceutical Executive March 1, 2014 William Looney	The Call to Community: A Conversation with Dr. David Nash Population health is the foundation for much of what is truly new in US health reform. For big Pharma, it represents yet another escalation in expectations.
Managed Care December 2005 John Carroll	Consumers Don't Know What They Don't Know Experts have been taking a close look at health literacy in America and have concluded that this is one area where even relatively well-educated people will have trouble finding their way.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Managed Care March 2004 Martin Sipkoff	Can Transparency Save Health Care? If everyone can see what everyone is doing, we'll have better care at lower costs. First task: Create common standards.
Pharmaceutical Executive September 1, 2012 Robin Hertz	The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
HBS Working Knowledge April 1, 2015 Carmen Nobel	The Slow, Steady Battle to Fix Cancer Care Thomas Feeley is on a quest to make payment procedures for cancer patients easier, hopefully less expensive, and in the process help change how health care is delivered in America.
HBS Working Knowledge November 22, 2004 Martha Lagace	Does the Medical Industry Deliver Value? When the discussion turns to healthcare reform, we get sidetracked on issues such as soaring costs. The real issue is, what is the most effective way to treat a disease or condition?
Pharmaceutical Executive June 1, 2014 Ben Comer	Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy.
Pharmaceutical Executive November 1, 2013 Jill Wechsler	Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.
Pharmaceutical Executive August 1, 2012	Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency.
The Motley Fool June 1, 2005 Stephen D. Simpson	Stent Wars: Revenge of the Bypass A new study supports a long-held belief that bypass surgery is better than using stents. What does it mean for stent makers and investors?
Managed Care January 2004 Martin Sipkoff	Cardiologists Call Collaboration Heart of Effort To Improve Care Surgeons in nine hospitals formed a study group and then hit the road to learn from peers. Outcomes improved dramatically.
Managed Care July 2003 Thomas Morrow	Drug-Eluting Stents To Transform Cardiovascular Medicine By reducing restenosis, these devices will save managed care money.
BusinessWeek August 8, 2005 Amy Barrett	BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals.
Managed Care December 2004 Adler & Schukman	The Role of Managed Care In Patient Safety & Error Reduction Patient safety and medical errors have become the focus of increasing attention from the public, policymakers, and accreditation agencies. Managed care organizations clearly are important stakeholders in this issue.
Managed Care February 2002 Mick L. Diede & Richard Liliedahl	Getting on the Right Track Converging forces are an economic train wreck waiting to happen. Avoiding a disaster requires an understanding of the interconnection of health care's stakeholders and the global consequences of their actions...
BusinessWeek September 9, 2010 Michelle Cortez	Coming Soon: Dissolvable Stents New stents from Abbott Labs and others appear to reduce the risk of blood clots
Managed Care August 2006 Emad Rizk	Finding Opportunity Where Business Models Meet The next stage of payer-provider collaboration will add true value.
The Motley Fool March 31, 2010 Brian Orelli	How Do You Put a Price on Pain? Price controls could wreck havoc on expensive therapies that control pain.
The Motley Fool June 30, 2011 Brian Orelli	Medical-Device Makers' Killer: Health-Care Inflation High prices have painted their targets.
Managed Care May 2002 John Carroll	Hospital Copayments: At What Cost? High daily copayments for high-priced hospitals are coming into fashion. It's all about shifting costs, but what about quality of care?
Fast Company May 2009 Chuck Salter	The Doctor of the Future Cost, access, quality -- the prognosis for American health care may look grim, but innovation is the cure. The medicine of tomorrow is being born today.
CFO February 1, 2007 Karen M. Kroll	Pin the Tail on the Doctor A dearth of information leaves health-care consumers in the dark. As health-care information becomes more accessible, will employees use it to purchase health-care services more intelligently?
BusinessWeek March 24, 2010 Nussbaum et al.	Obamacare's Cost Scalpel How does the health-care overhaul propose to control spending? By evaluating treatments through "comparative effectiveness research"
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
Managed Care July 2001 Maureen Glabman	Provider Shortage Puts HMOs In Bind Increasing demand for physicians and physician extenders is starting to strain the system. To a large extent, this is unexpected bitter fruit of managed care's labor...
CRM August 1, 2009 Lauren McKay	Healing the Sick Facing regulatory requirements, spiraling costs, and an aging (and ailing) customer base, the healthcare industry looks to CRM to balance a pair of age-old doctrines: First, do no harm - and physician, heal thyself.
The Motley Fool December 13, 2006 Stephen Albainy-Jenei	The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note.
CFO May 1, 2009 Josh Hyatt	Strong Medicine Boosted by a substantial injection of cash from the federal stimulus bill, electronic medical records may help relieve the pain of rising premiums by improving efficiencies in the medical system.
Knowledge@Wharton August 27, 2003	Code Blue: Combating Rising Healthcare Costs Calls for Strong Medicine It's been said many times over that the U.S. healthcare industry is a sick patient in search of a cure. The metaphor is a grim reflection of how the country is coping with an aging population, rising costs and an inefficient healthcare delivery system.
Managed Care April 2004 Martin Sipkoff	Plans Go Directly to Patients, Describing Treatment Options HMOs are developing programs that encourage patients to question their physicians about their treatment options. Doctors are wary.
Pharmaceutical Executive September 1, 2011	Should the US Gamble with Risk Sharing? Especially when payers come to the table holding the best cards, leaving industry second-guessing its strategy.
Financial Planning April 1, 2010 Rick Kahler	Healthcare on the Critical List Even if Congress does enact a new law, it seems that the same old problems will remain, at least for the next few years. So let's take a careful look at what's at stake.
BusinessWeek July 18, 2005	A Coronary Conundrum Four medical experts weigh in on whether heart surgery prolongs patients' lives or only relieves suffering.
Pharmaceutical Executive April 10, 2014	Obama Policies Reshape Pharma Marketing Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
HBS Working Knowledge June 29, 2015 Dina Gerdeman	Consumer-centered Health Care Depends on Accessible Medical Records John Quelch discusses approaches to integrate patient data so that medical professionals and patients can make better decisions.
The Motley Fool September 17, 2007 Brian Orelli	Can't See the Trees for the Forest Meta-analysis finds J&J's drug-coated stents are safer than Boston Scientific's stents, maybe. Can J&J use the complex study results to help their falling stent sales?
Managed Care May 2007 MargaretAnn Cross	Following the Leaders Top pay-for-performance programs point to increased focus on hospital incentives, efficiency measures, coordination, and standardization.
Pharmaceutical Executive August 1, 2005 Lena Chow	Docs of Shanghai They're short on status, pay, and respect, but China's young doctors hold keys to the world's fastest growing pharmaceutical market.
The Motley Fool March 29, 2007 Michael P. Cecil	Stents on Trial New study results could affect stent sales -- at least in the short term.